Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on December 8, 2020, reporting significant clinical data and regulatory developments. The company presented encouraging data for its BTK inhibitor, BRUKINSA® (zanubrutinib), at the 62nd American Society for Hematology (ASH) Annual Meeting. Key presentations included initial results from the Phase 2 MAGNOLIA trial for relapsed/refractory marginal zone lymphoma (MZL) and follow-up data from the Phase 3 SEQUOIA trial in treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with del(17p). Furthermore, BeOne Medicines announced the approval of BLINCYTO® (blinatumomab) in China for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This marks the first approval for BLINCYTO in China and the first product licensed from Amgen to be approved, positioning BLINCYTO as the first bispecific immunotherapy approved in China. These events highlight progress in the company's oncology pipeline and market expansion.
Key Highlights
- 1Presentation of clinical data for BRUKINSA® (zanubrutinib) at the 62nd ASH Annual Meeting, focusing on Marginal Zone Lymphoma (MZL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- 2Initial results from the Phase 2 MAGNOLIA trial for relapsed/refractory MZL were presented.
- 3Follow-up results from Arm C of the Phase 3 SEQUOIA trial in treatment-naïve CLL/SLL with del(17p) were shared.
- 4Clinical data on BRUKINSA® in B-cell malignancies intolerant to other BTK inhibitors (ibrutinib/acalabrutinib) were presented.
- 5First results from a pivotal Phase 2 trial for BRUKINSA® in relapsed/refractory Waldenström’s Macroglobulinemia (WM) were presented, supporting a China supplemental new drug application.
- 6Approval of BLINCYTO® (blinatumomab) by China's NMPA for adult R/R B-cell precursor ALL.
- 7BLINCYTO® is the first bispecific immunotherapy approved in China and BeiGene's first Amgen-licensed product approved in the region.